Tvardi Therapeutics (Nasdaq: TVRD) Soars on Positive Phase 1 Results for Next-Gen STAT3 Inhibitor TTI-109
· investorideas.com
Tvardi Therapeutics (Nasdaq: TVRD) shares surge after Phase 1 results show TTI-109 matched TTI-101's exposure with better tolerability and clear STAT3 target engagement.
Biotech · Stock Alert NASDAQ: TVRD
Tvardi's next-generation STAT3 inhibitor TTI-109 confirmed rapid prodrug conversion, dose-proportional exposure, and improv...